-
1
-
-
0025131974
-
Bioactive compounds from aquatic and terrestrial sources
-
Rinehart KL, Holt TG, Fregeau NL, Keifer PA, Wilson GR, Perun TJ Jr, et al. Bioactive compounds from aquatic and terrestrial sources. J Nat Prod 1990;53:771-92.
-
(1990)
J Nat Prod
, vol.53
, pp. 771-792
-
-
Rinehart, K.L.1
Holt, T.G.2
Fregeau, N.L.3
Keifer, P.A.4
Wilson, G.R.5
Perun Jr., T.J.6
-
2
-
-
0000448995
-
Advances in the chemistry and pharmacology of ecteinascidins, a promising new class of anti-cancer agents
-
Manzanares I, Cuevas C, Garcia-Nieto R, Marco E, Gago F. Advances in the chemistry and pharmacology of ecteinascidins, a promising new class of anti-cancer agents. Curr Med Chem Anticancer Agents 2001; 1:257-76.
-
(2001)
Curr Med Chem Anticancer Agents
, vol.1
, pp. 257-276
-
-
Manzanares, I.1
Cuevas, C.2
Garcia-Nieto, R.3
Marco, E.4
Gago, F.5
-
3
-
-
77958587933
-
Pm01183, a new dna minor groove covalent binder with potent in vitro and in vivo anti-tumour activity
-
Leal JF, Martinez-Diez M, Garcia-Hernandez V, Moneo V, Domingo A, Bueren-Calabuig JA, et al. PM01183, a new DNA minor groove covalent binder with potent in vitro and in vivo anti-tumour activity. Br J Pharmacol 2010;161:1099-110.
-
(2010)
Br J Pharmacol
, vol.161
, pp. 1099-1110
-
-
Leal, J.F.1
Martinez-Diez, M.2
Garcia-Hernandez, V.3
Moneo, V.4
Domingo, A.5
Bueren-Calabuig, J.A.6
-
4
-
-
84899016922
-
In vivo combination studies of PM01183 with alkylating, antimetabolites, DNA-topoisomerase inhibitors and tubulin binding agents [abstract]
-
April 2-6; Orlando FL. Philadelphia, PA: AACR; 2011. Abstract nr 3538
-
Guillen MJ, Catalu~na O, Palomares M, Lopez R, Cuevas C, Aviles P. In vivo combination studies of PM01183 with alkylating, antimetabolites, DNA-topoisomerase inhibitors and tubulin binding agents [abstract]. In: Proceedings of the AACR 102nd Annual Meeting; 2011 April 2-6; Orlando FL. Philadelphia, PA: AACR; 2011. Abstract nr 3538.
-
(2011)
Proceedings of the AACR 102nd Annual Meeting
-
-
Guillen, M.J.1
Cataluna, O.2
Palomares, M.3
Lopez, R.4
Cuevas, C.5
Aviles, P.6
-
5
-
-
80051585674
-
Trabectedin and its c subunit modified analogue pm01183 attenuate nucleotide excision repair and show activity toward platinum-resistant cells
-
Soares DG, Machado MS, Rocca CJ, Poindessous V, Ouaret D, Sarasin A, et al. Trabectedin and its C subunit modified analogue PM01183 attenuate nucleotide excision repair and show activity toward platinum-resistant cells. Mol Cancer Ther 2011;10:1481-9.
-
(2011)
Mol Cancer Ther
, vol.10
, pp. 1481-1489
-
-
Soares, D.G.1
Machado, M.S.2
Rocca, C.J.3
Poindessous, V.4
Ouaret, D.5
Sarasin, A.6
-
6
-
-
85015480531
-
Mechanism of action and antitumor activity of pm01183
-
Denver, Colorado; abstract
-
Aviles P, Galmarini C, Cuevas C, Guillen MJ, Frapolli R, Uboldi S, et al. Mechanism of action and antitumor activity of PM01183. 100th Annual Meeting of the American Association for Cancer Research (AACR); 2009; Denver, Colorado; abstract 2679.
-
(2009)
100th Annual Meeting of the American Association for Cancer Research (AACR
, pp. 2679
-
-
Aviles, P.1
Galmarini, C.2
Cuevas, C.3
Guillen, M.J.4
Frapolli, R.5
Uboldi, S.6
-
7
-
-
84862179405
-
The dna damage response to monofunctional anticancer dna binders
-
Soares DG, Larsen AK, Escargueil AE. The DNA damage response to monofunctional anticancer DNA binders. Drug Discov Today 2012; 9:59-67.
-
(2012)
Drug Discov Today
, vol.9
, pp. 59-67
-
-
Soares, D.G.1
Larsen, A.K.2
Escargueil, A.E.3
-
9
-
-
0005932350
-
-
The European Agency for the Evaluation of Medicinal Products Human Medicines Evaluation Unit
-
The European Agency for the Evaluation of Medicinal Products Human Medicines Evaluation Unit. Note for guidance on the pre-clinical evaluation of anticancer medicinal products. 1998. http://www.iss.it/binary/scf1/cont/CPMP- SWP-997-96.pdf.
-
(1998)
Note for Guidance on the Pre-Clinical Evaluation of Anticancer Medicinal Products
-
-
-
11
-
-
10244241837
-
Phase i clinical trial of cep-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors
-
Undevia SD, Vogelzang NJ, Mauer AM, Janisch L, Mani S, Ratain MJ. Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors. Invest New Drugs 2004;22:449-58.
-
(2004)
Invest New Drugs
, vol.22
, pp. 449-458
-
-
Undevia, S.D.1
Vogelzang, N.J.2
Mauer, A.M.3
Janisch, L.4
Mani, S.5
Ratain, M.J.6
-
13
-
-
0034594628
-
New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer institute of the united states, national cancer institute of canada
-
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92: 205-16.
-
(2000)
J Natl Cancer Inst
, vol.92
, pp. 205-216
-
-
Therasse, P.1
Arbuck, S.G.2
Eisenhauer, E.A.3
Wanders, J.4
Kaplan, R.S.5
Rubinstein, L.6
-
16
-
-
33745515076
-
American society of clinical oncology guideline for antiemetics in oncology: Update 2006
-
Kris MG, Hesketh PJ, Somerfield MR, Feyer P, Clark-Snow R, Koeller JM, et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 2006;24:2932-47.
-
J Clin Oncol
, vol.2006
, Issue.24
, pp. 2932-2947
-
-
Kris, M.G.1
Hesketh, P.J.2
Somerfield, M.R.3
Feyer, P.4
Clark-Snow, R.5
Koeller, J.M.6
|